VVOS Earnings Date: Nov 18, 2026 (Estimated) — Vivos Therapeutics, Inc.
NASDAQ · Healthcare · Medical Devices
Updated
When is VVOS's next earnings date?
Vivos Therapeutics, Inc. (VVOS) is expected to report Q3 2026 earnings on Wednesday, November 18, 2026 at 4:00 PM ET (after market close); the date is an estimate and has not been confirmed by the company. The consensus estimate is EPS of -$0.30 on revenue of $5.5M.
How did VVOS do in its last earnings report?
In its most recent report on Aug 14, 2026 (Q2 2026), Vivos Therapeutics, Inc. posted EPS of -$0.31 versus the -$0.41 estimate, a beat of 22.5%. Revenue was $5.2M against a $5.6M estimate. The stock's 1-day post-earnings move was -12.3%.
How much does VVOS stock move after earnings?
VVOS beat EPS estimates in 5 of its last 8 reported quarters. Over the last 8 reports the stock moved an average of 9.3% (up or down) in the day after earnings.
About Vivos Therapeutics, Inc.
Vivos Therapeutics, Inc. operates as a medical technology company that develops and commercializes treatment modalities for patients with dentofacial abnormalities, obstructive sleep apnea (OSA), and snoring in adults. It offers The Vivos Method, a non-invasive, non-surgical, non-pharmaceutical, multi-disciplinary treatment modality for the treatment of dentofacial abnormalities, OSA, and snoring. The company also offers VivoScore Program, a screening and home sleep test in adults and children. It markets and sells its appliances, and related treatments and services to licensed professionals, primarily general dentists in the United States and Canada. The company was formerly known as Vivos BioTechnologies, Inc. and changed its name to Vivos Therapeutics, Inc. in March 2018. The company was founded in 2016 and is based in Littleton, Colorado.
Earnings History
| Date | Period | EPS Est. | EPS Act. | Surprise | Revenue | Result | 1D Δ | 1W Δ | 1M Δ |
|---|---|---|---|---|---|---|---|---|---|
| 2026-08-14 | Q2 2026 | -0.41 | -0.31 | +22.50% | $5.2M | ✅ Beat | -12.26% | -13.49% | -52.34% |
| 2026-05-20 | Q1 2026 | -0.45 | -0.52 | -15.56% | $5.1M | ❌ Miss | -0.88% | +13.56% | -31.83% |
| 2026-04-15 | Q4 2025 | -0.47 | -0.58 | -23.40% | $3.8M | ❌ Miss | -25.85% | -29.93% | -53.06% |
| 2025-11-19 | Q3 2025 | -0.52 | -0.49 | +5.77% | $6.8M | ✅ Beat | -10.17% | -5.08% | -16.53% |
| 2025-08-19 | Q2 2025 | -0.38 | -0.55 | -44.74% | $3.8M | ❌ Miss | -3.28% | +9.84% | -21.78% |
| 2025-03-31 | Q4 2024 | -0.43 | -0.28 | +34.88% | $3.7M | ✅ Beat | -7.72% | -11.58% | -0.35% |
| 2024-11-14 | Q3 2024 | -0.70 | -0.40 | +42.86% | $3.9M | ✅ Beat | -8.97% | -5.45% | +58.65% |
| 2024-08-14 | Q2 2024 | -1.05 | -0.60 | +42.86% | $4.1M | ✅ Beat | -5.11% | +19.70% | +24.47% |
Showing last 8 quarters.
Revenue by segment & region
By segment
Q2 FY26 · $6.9M total
| Segment | Share | Revenue | YoY | Q4 FY24 | Q1 FY25 | Q2 FY25 | Q3 FY25 |
|---|---|---|---|---|---|---|---|
| Service | 55.3% | $3.8M | +96.3% | $1.4M | $1.2M | $1.9M | $4.6M |
| Product | 19.7% | $1.4M | -28.1% | $2.3M | $1.8M | $1.9M | $2.2M |
| Treatment Centers | 11.2% | $767K | — | — | — | — | $1.3M |
| Appliances | 9.3% | $640K | -37.7% | $1.3M | $1.3M | $1.0M | $1.4M |
| Sponsorship Seminar Other | 2.3% | $161K | -73.5% | $1.3M | $328K | $608K | — |
| Billing Intelligence Services | 1.9% | $129K | -32.1% | $196K | $181K | $190K | $184K |
| VIP | 0.2% | $12K | -90.8% | — | $223K | $130K | $82K |
Source: company filings via FMP. YoY compares the same fiscal period a year earlier.